BioMedNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Launches BreastCT.com to Advance Awareness of Dedicated Breast CT Technology

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company commercializing imaging-based products for more accurate breast cancer screening, diagnoses, and treatment, announced the launch of BreastCT.com, a new online platform supporting its awareness initiatives. The site serves as a central educational resource on dedicated breast CT technology and Izotropic’s IzoView Breast CT Imaging System, emphasizing its potential to address challenges in detecting cancer in the 50% of women with dense breast tissue. With IzoView’s engineering complete, the platform will evolve with the Company through clinical study preparation, U.S. and global regulatory phases, and ongoing awareness programs leading to commercial launch. The content also positions Izotropic within a broader industry context by highlighting other public companies that successfully created new imaging categories, offering audiences perspective on where IzoView could fit within the market ahead of regulatory and commercial milestones.

To view the full press release, visit https://ibn.fm/QEOJ4

About Izotropic

More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedarplus.ca

NOTE TO INVESTORS: The latest news and updates relating to IZOZF are available in the company’s newsroom at https://ibn.fm/IZOZF

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN